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A B S T R A C T
Glomerular epithelial cells, podocytes, are insulin responsive and can develop insulin resistance. Here, we
demonstrate that the small GTPase septin 7 forms a complex with nonmuscle myosin heavy chain IIA (NMHC-
IIA; encoded byMYH9), a component of the nonmuscle myosin IIA (NM-IIA) hexameric complex. We observed
that knockdown of NMHC-IIA decreases insulin-stimulated glucose uptake into podocytes. Both septin 7 and
NM-IIA associate with SNAP23, a SNARE protein involved in GLUT4 storage vesicle (GSV) docking and fusion
with the plasma membrane. We observed that insulin decreases the level of septin 7 and increases the activity of
NM-IIA in the SNAP23 complex, as visualized by increased phosphorylation of myosin regulatory light chain.
Also knockdown of septin 7 increases the activity of NM-IIA in the complex. The activity of NM-IIA is increased
in diabetic rat glomeruli and cultured human podocytes exposed to macroalbuminuric sera from patients with
type 1 diabetes. Collectively, the data suggest that the activity of NM-IIA in the SNAP23 complex plays a key role
in insulin-stimulated glucose uptake into podocytes. Furthermore, we observed that septin 7 reduces the activity
of NM-IIA in the SNAP23 complex and thereby hinders GSV docking and fusion with the plasma membrane.
1. Introduction
Diabetic nephropathy (DN) is a serious complication of diabetes
and the most common cause of end-stage renal disease [1]. Much eﬀort
has therefore been devoted to understanding the mechanisms that
promote glomerular damage in DN. Risk factors for the development of
DN include, for example, hyperglycemia, hypertension, dyslipidemia
and genetic factors [2]. Also insulin resistance is a risk factor for DN
[2], and has been reported to be associated with microalbuminuria in
patients with type 1 as well as type 2 diabetes [3,4].
At the cellular level the mechanisms leading to the development of
insulin resistance include mutations in the insulin receptor itself [5]
and impairments in the phosphoinositide 3-kinase (PI3K)/Akt signal-
ing pathway which mediates the uptake of glucose into cells [6].
Glucose transporter 4 (GLUT4) is the major insulin-inducible glucose
transporter. Insulin activates the translocation of GLUT4 storage
vesicles (GSVs) from the intracellular storage site to the plasma
membrane [7]. GSV traﬃcking consists of several steps, and distur-
bances in this traﬃcking process may also cause insulin resistance. The
traﬃcking involves actin and microtubule networks, the exocyst
complex proteins that help to tether the GSVs with the plasma
membrane, and the soluble N-ethylmaleimide–sensitive fusion protein
attachment protein receptor (SNARE) complex that facilitates the
tethering, docking and fusion of GSVs with the plasma membrane.
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The SNARE complex includes a vesicle-SNARE on GSVs, such as
vesicle-associated membrane protein 2 (VAMP2), and target-SNAREs
on the plasma membrane, such as syntaxin 4 and synaptosomal-
associated protein, 23 kDa (SNAP23) [7].
Interestingly, kidney glomerular epithelial cells, or podocytes, are
insulin sensitive and able to rapidly transport glucose using the glucose
transporters GLUT4 and GLUT1 [8]. Insulin signaling is necessary for
normal kidney function, as deletion of insulin receptor speciﬁcally in
podocytes induces a disease state reminiscent of DN in a normogly-
cemic environment [9]. Furthermore, podocytes isolated from diabetic
db/db mice are unable to respond to insulin indicating that podocytes
can develop insulin resistance [10]. Nephrin, an essential structural
protein of the glomerular ﬁltration barrier, aids in GSV docking by
interacting with the v-SNARE VAMP2 [11]. We showed previously that
the small GTPase septin 7 associates with nephrin and VAMP2, and
negatively regulates glucose uptake in podocytes [12]. Our data further
revealed that knockdown of septin 7 increased the complex formation
of VAMP2 with nephrin and syntaxin 4 [12], indicating that depletion
of septin 7 enhances the ﬁnal stages of GSV exocytosis.
In this study we set out to deﬁne whether septin 7 plays a speciﬁc,
regulatory role in the docking of the GSVs with the plasma membrane
as suggested by its association with nephrin [12]. We found that
nonmuscle myosin heavy chain IIA (NMHC-IIA), which regulates the
docking and fusion of GSVs in adipocytes [13–15], is a novel interac-
tion partner of septin 7. Speciﬁcally, we observed that septin 7 reduces
the activity of nonmuscle myosin IIA (NM-IIA) in the SNAP23-
containing SNARE complex at the plasma membrane. Our study thus
proposes a novel mechanism by which septin 7, by reducing the activity
of NM-IIA in the SNAP23 complex, hinders GSV docking and fusion
with the plasma membrane and reduces glucose uptake into podocytes.
2. Materials and methods
2.1. Cell culture, stable overexpression of nephrin in podocytes and
preparation of cell lysates
Conditionally immortalized human podocytes (AB 8/13) were
maintained in RPMI-1640 supplemented with 10% fetal calf serum
(FCS) and 1% ITS (Sigma-Aldrich, St. Louis, MO) at 33 °C and shifted
to 37 °C for two weeks for diﬀerentiation [16]. Rat nephrin was
previously subcloned into pLNCX2 retroviral vector [17]. HEK293T
cells were co-transfected with pLNCX2-nephrin and packaging pKAT2
vectors using Lipofectamine 2000 (Invitrogen, Camarillo, CA, USA).
Virus-containing medium was ﬁltered through a 0.45 µm ﬁlter and
used to infect mouse podocytes. Podocytes overexpressing nephrin
were selected by culturing the cells in medium supplemented with
2,5 mg/ml of geneticin (G418) (Gibco, Life Technologies, Carlsbad, CA,
USA) for 12 days. Mouse podocytes and mouse podocytes stably
overexpressing nephrin were maintained in DMEM containing 4.5 g/
L glucose, 10% FCS, penicillin and streptomycin (Sigma-Aldrich),
supplemented with 10 U/ml INF-γ (Sigma-Aldrich) at 33 °C. Where
indicated, podocytes were starved and stimulated with 20 nM insulin
(NovoNordisk, Bagsværd, Denmark). HEK293T cells were maintained
in DMEM supplemented with 10% FCS, 1% ultraglutamin, 1%
streptomycin and 1% penicillin at 37 °C. Cells were lysed in 1%
Nonidet P-40 (NP-40), 20 mM HEPES, pH 7.5, 150 mM NaCl, in
50 mM HEPES, pH 7.6, 0.5% Triton X-100, 0.5% CHAPS or in 0.5%
NP-40, 100 mM NaCl, 20 mM Tris-HCl, pH 8.0, 1 mM EDTA for co-
immunoprecipitation as described [12]. All lysis buﬀers were supple-
mented with 50 mM NaF, 1 mM Na3VO4 and 1x Complete proteinase
inhibitor cocktail (Roche, Basel, Switzerland).
2.2. Immunoprecipitation
Lysates were precleared with protein A-Sepharose (Invitrogen) or
TrueBlot® anti-rabbit or anti-mouse Ig IP beads (eBiosciences, San
Diego, CA, USA) and incubated with anti-septin 7, anti-SNAP23 or
anti-nephrin antibodies and normal rabbit serum or rabbit/mouse IgGs
(Zymed, South San Francisco, CA) as controls at 4 °C for 16 h. The
immune complexes were bound to protein A-Sepharose or TrueBlot
beads, washed with lysis buﬀer, stained with GelCode Blue (Pierce
Chemical Co, Rockford, IL) or immunoblotted as described below.
2.3. Protein identiﬁcation by LC-MS/MS
For mass spectrometry analysis the precipitated proteins were
separated by SDS-PAGE and stained with GelCode Blue (Pierce
Chemical Co). The > 200 kDa band obtained in the septin 7 immuno-
precipitation was excised from gel, in-gel digested with trypsin and the
resulting peptides were analyzed by LC-MS/MS using an Ultimate
3000 nano-LC (Dionex, Sunnyvale, CA) and a QSTAR Elite hybrid
quadrupole TOF-MS (Applied Biosystems/MDS Sciex, Life
Technologies, Carlsbad, CA) with nano-ESI ionization as described
previously [18]. The LC-MS/MS data was searched with in-house
Mascot through ProteinPilot 2.0 interface against the SwissProt
database using criteria: Human-speciﬁc taxonomy, trypsin digestion
with one missed cleavage allowed, carbamidomethyl modiﬁcation of
cysteine as a ﬁxed modiﬁcation and oxidation of methionine as a
variable modiﬁcation.
2.4. Preparation of tissue lysates
Glomerular and tubular fractions were isolated from kidney cortices
of male Sprague-Dawley and 40 weeks old, albuminuric obese or lean
Zucker rats by graded sieving [19]. Zucker rats (Crl: ZUC-Leprfa) were
purchased from Charles River Laboratories (Sulzfeld, Germany). Blood
glucose, urinary albumin, and creatinine measurements have been
described in [20]. The protocols were approved by the National Animal
Experiment Board. Tissue lysates were prepared as above in NP-40
lysis buﬀer or in 50 mM HEPES, pH 7.6, 0.5% Triton X-100, 0.5%
CHAPS.
2.5. Antibodies
Goat anti-septin 7 (N12) and rabbit anti-septin 7 (H120) IgGs were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and rabbit anti-
septin 7 (C) IgG was from Immuno-Biological Laboratories Co., Ltd.
(Gumma, Japan). Rabbit anti-nonmuscle myosin IIA heavy chain IgG
was from Biomedical Technologies, Inc. (Stoughton, MA, USA), and
rabbit anti-phospho-myosin light chain 2 (Thr18/Ser19) IgG from Cell
Signaling (Danvers, MA, USA). Rabbit anti-nephrin IgG (#1034) is
described in [21], and mouse anti-nephrin IgG (5-1-6) in [22]. Guinea
pig anti-nephrin IgG was from PROGEN Biotechnik (Heidelberg,
Germany), and rabbit anti-SNAP23 and mouse anti-VAMP2 IgGs were
from Synaptic System (Goettingen, Germany). Mouse anti-SNAP23,
mouse anti-tubulin and mouse anti-actin IgGs were from Sigma-
Aldrich.
2.6. Immunoblotting
Glomerular lysates of 40 weeks old six individual obese Zucker (fa/
fa) and six individual lean Zucker (fa/+) rats were used for analyzing
NMHC-IIA, septin 7 and pp-RLC expression levels. Diﬀerentiated
human podocytes were exposed to 10% patient sera in FCS-free culture
medium for 48 h. The serum samples were from 4 normoalbuminuric
and 5 macroalbuminuric patients with type 1 diabetes from the Finnish
Diabetic Nephropathy Study (FinnDiane; www.ﬁnndiane.ﬁ)
(Supplemental Table S1). Immunoblotting was performed as in [17]
and blots were quantiﬁed using an Odyssey Infrared Imaging System
(LI-COR, Lincoln, NE, USA).
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2.7. Immunoperoxidase staining
Human kidney samples were collected from surgical nephrectomies
performed at Helsinki and Uusimaa Hospital district, and represented
the non-malignant part of the kidney. Samples were ﬁxed with 10%
formalin, dehydrated, and embedded in paraﬃn. Immunoperoxidase
staining was performed with a VectaStain Elite kit (Vector
Laboratories, Burlingame, CA, USA). Sections were deparaﬃnized,
antigen retrieval was performed by boiling in a microwave oven in
10 mM citric acid, pH 6.0 for 15 min, and endogenous peroxidase was
inactivated by incubation in hydrogen peroxide in methanol for 30 min.
Sections were blocked with CAS-block (Invitrogen) and incubated with
primary antibodies diluted in ChemMate™ (DakoCytomation,
Glostrup, Denmark) and with biotinylated secondary antibodies fol-
lowed by incubation with ABC-reagent and AEC (Sigma-Aldrich) for
colour development. Sections were counterstained with hematoxylin,
mounted with Shandon Immu-Mount (Thermo Scientiﬁc, Waltham,
MA, USA) and photographed using Nikon Eclipse 800 microscope. The
use of human material was approved by the local Ethics Committee.
2.8. Immunoelectron microscopy
Adult rat kidney samples were ﬁxed with 4% PFA in 0.1 M sodium
phosphate buﬀer, pH 7.4 for 4 days at room temperature and infused
with 2.3 M sucrose in PBS at 4 °C over night [23]. Ultrathin frozen
sections were quenched with 50 mM NH4Cl in PBS for 10 min, blocked
with 1% ﬁsh skin gelatin, 1% BSA in NH4Cl in PBS for 10 min, and
incubated with rabbit anti-septin 7 (C) IgG followed by 10-nm gold-
conjugated protein A (Department Cell Biology, Utrecht School of
Medicine, the Netherlands), both incubations in a humidiﬁed chamber
at room temperature for 60 min. Grids were stained in 2% neutral
uranyl acetate for 10 min at room temperature, quickly rinsed and
incubated in 2% methyl cellulose, 2% uranyl acetate (Sigma-Aldrich)
for 15 min on ice. Samples were examined with JEM-1400
Transmission Electron Microscope (Jeol, Akishima, Tokyo, Japan)
equipped with Olympus-SIS Morada CCD camera (Olympus Soft
Imaging Solutions GmbH, Münster, Germany).
2.9. Indirect immunoﬂuorescence
Surface labeling of nephrin was performed with nephrin IgG (5-1-
6) as described in [19] using AlexaFluor 555 donkey anti-mouse IgG
(Molecular Probes) as the secondary antibody. Nuclei were visualized
with Hoechst 33342 (Sigma-Aldrich). Samples were examined with
Leica SP8 confocal microscope (Wetzlar, Germany).
2.10. Duolink in situ
Interactions of SNAP23 with septin 7, NMHC-IIA, pp-RLC or
VAMP2 were detected by the proximity ligation assay kit Duolink:
PLA probe anti-rabbit plus, PLA probe anti-mouse minus (Olink
Bioscience, Uppsala, Sweden). The samples were processed following
the manufacturer's instructions and the ﬂuorescence images were
captured using Zeiss Axioplan2 microscope. Quantiﬁcation of the
detected PLA signals was performed using the Duolink Image Tool
(Olink Bioscience). All samples were investigated with equal light
intensity. Sensitivity of the software scan and blob threshold were set
identically for all probes. The positive reaction dots from each
interaction were counted automatically from at least 100 cells.
2.11. Silencing nonmuscle myosin IIA and septin 7 by siRNA
Mouse podocytes were transfected with 150 nmol ON-TARGET
plus SMARTpool mouse nonmuscle myosin IIA heavy chain (L-
040013-00-0005), siGENOME SMARTpool mouse septin 7 (M-
042160-01-0005) or siCONTROL Non-Targeting Pool#2 (D-001206-
14-05) siRNAs (Dharmacon, Lafayette, CO, USA) using Lipofectamine
2000 (Invitrogen). Cells were used for experiments after 48 h (NMHC-
IIA siRNA) or 72 h (septin 7 siRNA).
2.12. 2-deoxy-D-glucose uptake assay
Glucose uptake of mouse podocytes was measured using 50 µmol/L
(1 µCi/ml) 2-deoxy-D-[(1, 2-3H(N)]-glucose (PerkinElmer, Boston,
MA) as described [12].
2.13. Statistical analysis
In all experiments, the diﬀerences between the groups were
evaluated with the Student's t-test (Microsoft Excel). Sex frequencies
were compared between cases and controls with the χ2 test. Results are
presented as means ± STDEV.
3. Results
3.1. Nonmuscle myosin heavy chain IIA interacts with septin 7 in
podocytes
To deﬁne the role of septin 7 in podocytes and speciﬁcally in the
regulation of GSV traﬃcking, we set out to identify novel interaction
partners of septin 7. Co-immunoprecipitation analysis of human
podocytes with anti-septin 7 antibodies identiﬁed a > 200 kDa protein
which associates with septin 7 (Fig. 1A). The corresponding band was
excised from the gel, and the protein was identiﬁed by LC-MS/MS as
NMHC-IIA. Two myosin heavy chains (MHCs) together with two pairs
of light chains, essential light chains (ELCs) and regulatory light chains
(RLCs) form the hexameric NM-II complex [24]. The NMHC-IIA
isoform is encoded by the MYH9 gene [25] and it has previously been
shown to be expressed in podocytes [26]. Co-immunoprecipitation and
Western blotting conﬁrmed that septin 7 and NMHC-IIA form a
complex in cultured human and mouse podocytes in the basal state,
and in isolated rat glomeruli (Fig. 1B). Immunoperoxidase staining
indicated that septin 7 and NMHC-IIA are expressed in podocytes in
human kidneys in vivo (Fig. 1C and D). Immunogold electron micro-
scopy further conﬁrmed that septin 7 is expressed in podocyte foot
processes as well as in endothelial cells in glomeruli (Fig. 1E and F).
3.2. NMHC-IIA binds to nephrin and the SNARE complex
In adipocytes, NM-IIA has been shown to regulate glucose uptake
by inﬂuencing the docking and fusion of GSVs as well as the activity of
GLUT4 [13–15]. This suggests that septin 7 could, together with
NMHC-IIA, regulate glucose uptake into podocytes by regulating the
docking step. We next analyzed whether septin 7, nephrin, NM-IIA,
and the plasma membrane SNARE proteins are part of the same
macromolecular protein complex in the basal state. To mimic podo-
cytes in vivo as closely as possible, we ﬁrst produced a podocyte cell
line stably expressing nephrin, as nephrin expression is typically lost
from cultured podocytes during early passages. Nephrin was intro-
duced into mouse podocytes by retroviral infection and cells stably
expressing nephrin were obtained by antibiotic selection. Western
blotting and surface labeling conﬁrmed stable expression of nephrin
in podocytes (Fig. 1G–I).
Immunoprecipitation analysis revealed that nephrin complex con-
tains NMHC-IIA as well as septin 7 and SNAP23, a component of the t-
SNARE complex at the plasma membrane (Fig. 1J). We further
conﬁrmed by co-immunoprecipitation with anti-SNAP23 antibodies
that septin 7 and NMHC-IIA co-immunoprecipitate with SNAP23
(Fig. 1K). Further, as phosphorylation of the RLC regulates myosin
motor activity [27] and GSV translocation and glucose uptake in
adipocytes [28], we also studied the activity of NM-IIA in the
SNAP23 complex by analyzing the presence of phosphorylated RLC
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(pp-RLC) in the complex. We found that NM-IIA, as visualized by the
presence of pp-RLC in the precipitates, was active in the SNAP23
complex in podocytes (Fig. 1K).
To verify the interactions, we performed a Duolink proximity
ligation assay (PLA) in which the interaction of the proteins can be
visualized by immunoﬂuorescence microscopy in the cells in situ. The
method is based on application of speciﬁc primary antibodies raised in
diﬀerent species, followed by proximity probes (secondary antibodies
coupled with oligonucleotides) and a connector oligonucleotide that
produces a template for ligation and subsequent rolling circle PCR
ampliﬁcation. Each detected interaction gives rise to one rolling circle
ampliﬁcation product and consequently, quantiﬁcation of the number
of ﬂuorescent spots observed reﬂects the level of interaction between
the two proteins analyzed [29]. A previous study has conﬁrmed that the
method is suitable to analyze the SNARE complex formation [30].
Consistent with the co-immunoprecipitation data, Duolink showed that
SNAP23 forms a complex with NMHC-IIA and septin 7 in mouse
podocytes, and that NM-IIA is active in the complex as conﬁrmed by
the phosphorylation of the RLC (Fig. 1L–O).
3.3. NMHC-IIA reduces insulin-stimulated glucose uptake into
podocytes
We next deﬁned whether NM-IIA aﬀects glucose uptake into
podocytes by using previously characterized siRNAs speciﬁc for
NMHC-IIA [15,31] to reduce the expression level NMHC-IIA followed
by glucose uptake assay. We observed that reduction of NMHC-IIA
expression in nephrin-expressing podocytes by 68% (Fig. 2A and B)
does not aﬀect glucose uptake in basal (Fig. 2C) and starved states
(Fig. 2D), but decreases insulin-stimulated glucose uptake by 56%
compared to control siRNA-transfected, nonstimulated cells (set to
100%; Fig. 2D). In control siRNA-transfected cells insulin stimulation
increases glucose uptake by 73% (Fig. 2D).
Fig. 1. Nonmuscle myosin IIA is a novel interaction partner of septin 7 and it binds to the SNARE complex and nephrin (A) GelCode Blue-stained gel of immunoprecipitates obtained
with septin 7 or rabbit IgGs from cultured human podocytes. The > 200 kDa band (*) present only in the septin 7 precipitate was identiﬁed by mass spectrometry as nonmuscle myosin
heavy chain IIA (NMHC-IIA). (B) Immunoblots showing NMHC-IIA in immunoprecipitates obtained with septin 7 IgG but not with rabbit IgG from human podocytes (hu pod), mouse
podocytes (ms pod) or rat glomeruli (rt glom). Podocyte or glomerular lysates (30 µg) are included as controls. (C–D) Immunohistochemical staining shows that septin 7 (C) and NMHC-
IIA (D) are expressed in podocytes in human glomeruli (arrowheads). (E–F) Immunogold electron microscopy of rat glomeruli shows septin 7 localization in podocyte foot processes
(arrowheads) and endothelial cells (arrows). E, endothelial cell; FP, foot process; GBM, glomerular basement membrane. (G) In mouse podocytes stably expressing nephrin (nephrin
OE), nephrin appears as an ∼180 kDa band that migrates slightly slower than the major band of endogenous nephrin in isolated rat glomeruli. Nephrin is not detected endogenously in
podocytes (podocytes wt) or in podocytes infected with vector alone (vector). Actin is included as a loading control. (H–I) Surface labeling followed by confocal microscopy analysis
conﬁrms the localization of nephrin at the plasma membrane in podocytes overexpressing nephrin (H) whereas no signal is observed when the primary antibody is omitted (I). (J)
Immunoblots showing NMHC-IIA, septin 7 and SNAP23 in immunoprecipitates obtained with nephrin IgG but not with rabbit IgG. Mouse podocyte lysate (30 µg) is included as a
control. (K) Immunoblots showing NMHC-IIA, septin 7 and pp-RLC in immunoprecipitates obtained with SNAP23 IgG but not with rabbit IgG. Mouse podocyte lysate (30 µg) is
included as a control. (L–O) Duolink proximity ligation assay shows interaction between SNAP23 and NMHC-IIA (L), septin 7 (M) and pp-RLC (N) in mouse podocytes. Each red spot
represents an interaction detected by the kit. Scale bar, 50 µm (C, D), 0.5 µm (E–F), and 30 µm (H, I, L–O).
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3.4. Downregulation of NMHC-IIA inhibits the association of VAMP2
with SNAP23
We further investigated the mechanism of attenuated insulin-
stimulated glucose uptake in NMHC-IIA-depleted podocytes by study-
ing the complex formation between the proteins on the GSVs and the
plasma membrane. We speculated that in the absence of NMHC-IIA
the complex formation between v-SNAREs and t-SNARES could be
reduced. Indeed, we observed that in NMHC-IIA knockdown podocytes
insulin stimulation fails to enhance complex formation between
VAMP2 and SNAP23 compared to control siRNA-transfected, insu-
lin-stimulated cells (Fig. 3A and B). Consistent with the co-immuno-
precipitation data, Duolink showed decreased interaction of VAMP2
with SNAP23 in NMHC-IIA-depleted podocytes compared to the
control siRNA-treated podocytes after insulin stimulation (Fig. 3C–
G). This indicates that depletion of NMHC-IIA inhibits the insulin-
induced complex formation between the v-SNARE VAMP2 and the t-
SNARE SNAP23, and thereby reduces docking and fusion of the GSVs
with the plasma membrane in podocytes, concomitant with reduced
insulin-stimulated glucose uptake.
3.5. Insulin regulates the activity of NM-IIA bound to SNAP23
As knockdown of NMHC-IIA in podocytes reduces insulin-induced
glucose uptake and as septin 7 and active NM-IIA bind to SNAP23, one
could expect that insulin regulates the complex formation, or the
activity of NM-IIA in complex with SNAP23. To investigate this, we
performed co-immunoprecipitation and Duolink proximity ligation
assays with and without insulin stimulation in podocytes. We found
that insulin stimulation decreases the association of septin 7 with
SNAP23 (Fig. 4A–D, G, H and K). However, insulin increases the
activity of NM-IIA bound to SNAP23 as visualized by an increase of pp-
RLC in the immunoprecipitate with SNAP23 and as also observed by
the proximity ligation assay (Fig. 4C, F, I, J and L) without aﬀecting the
amount of NMHC-IIA in complex with SNAP23 (Fig. 4C and E). The
data indicate an important regulatory role for the SNAP23 protein
complex in glucose uptake into podocytes, insulin reducing the level of
septin 7 in the complex with concomitant stimulation of the activity of
NM-IIA in the complex.
Fig. 2. NMHC-IIA regulates insulin-stimulated glucose uptake in podocytes. (A) NMHC-IIA siRNA leads to 68% reduction of NMHC-IIA expression in mouse podocytes. Tubulin is
included as a loading control. (B) Quantiﬁcation of NMHC-IIA level in three replicate blots as in (A). (C) Depletion of NMHC-IIA does not aﬀect glucose uptake activity of mouse
podocytes compared to the control siRNA transfected cells (set to 100%) under basal conditions. (D) Knockdown of NMHC-IIA (NMHC-IIA siRNA, -insulin) does not aﬀect glucose
uptake activity of serum starved mouse podocytes. Glucose uptake activity of the control siRNA transfected and serum starved cells is set to 100% (control siRNA, -insulin). Insulin
stimulation increases glucose uptake 73% in control siRNA transfected cells (control siRNA, +insulin), but decreases glucose uptake by 56% in myosin IIA siRNA transfected cells
(NMHC-IIA siRNA, +insulin) compared to the control (control siRNA, -insulin). Bars show the mean and error bars STDEV of three independent experiments, Student's t-test. * p <
0.05, ** p < 0.01.
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3.6. Septin 7 knockdown decreases the amount but increases the
activity of NM-IIA in complex with SNAP23
We next addressed whether septin 7 knockdown aﬀects the activity
of NM-IIA in the SNAP23 complex. To study this, we used septin 7-
speciﬁc siRNAs [12] to knock down septin 7 in mouse podocytes
followed by co-immunoprecipitation using an anti-SNAP23 antibody
and immunoblotting for the complex components. We found that
depletion of septin 7 decreases the interaction between SNAP23 and
NMHC-IIA (Fig. 5A and B). However, depletion of septin 7 increases
the activity of NM-IIA in complex with SNAP23 as visualized by
increased level of pp-RLC in the SNAP23 immunoprecipitate (Fig. 5A
and C). The interactions were further analyzed by the Duolink
proximity ligation assay (Fig. 5D–I), which conﬁrmed the data
obtained by co-immunoprecipitation assays indicating that septin 7
enhances the complex formation between NM-IIA and SNAP23, and
that suppression of septin 7 expression increases the activity of NM-IIA
in complex with SNAP23. It is noteworthy that the increase in the
activity of NM-IIA in complex with SNAP23 is not due to overall
changes in the expression level or activity of NM-IIA, as Western
blotting of whole cell lysates for NMHC-IIA and pp-RLC reveals no
diﬀerences between septin 7 siRNA and control siRNA -transfected
cells (Fig. 5J–M), as also shown previously [32].
3.7. Septin 7 overexpression increases the amount but decreases the
activity of NM-IIA in complex with SNAP23
To conﬁrm the septin 7 knockdown data, we investigated the eﬀect
of septin 7 overexpression on the activity of NM-IIA in complex with
SNAP23. We ﬁrst conﬁrmed that septin 7 overexpression reduces
glucose uptake as expected by performing 2-deoxy-D-glucose uptake
assay on septin 7 overexpressing podocytes. Overexpression of septin 7
led to 1.6-fold upregulation of septin 7 (Supplemental Fig. S1A–E). 2-
deoxy-D-glucose uptake assay indicated that glucose uptake is de-
creased by 20% in septin 7-overexpressing podocytes compared to
empty vector-transfected cells (set to 100%) under basal conditions
(Supplemental Fig. S1F). In serum-starved podocytes, overexpression
of septin 7 did not aﬀect glucose uptake compared to empty vector-
transfected cells (set to 100%; Supplemental Fig. S1G). Insulin
stimulation of podocytes increased glucose uptake in empty vector-
transfected cells by 33% (Supplemental Fig. S1G), whereas the glucose
uptake activity remained unchanged in septin 7-overexpressing podo-
cytes (Supplemental Fig. S1G). These results conﬁrm that septin 7 is a
negative regulator of glucose uptake into podocytes as we showed
previously [12].
As expected, we found that septin 7 overexpression increases the
complex formation between NMHC-IIA and SNAP23 (Fig. 6A–B), but
decreases the activity of NM-IIA found in complex with SNAP23, as
Fig. 3. Knockdown of NMHC-IIA inhibits the interaction between VAMP2 and SNAP23. (A) Immunoblots showing VAMP2 in immunoprecipitates obtained with SNAP23 IgG but not
with rabbit IgG from control or NMHC-IIA siRNA transfected mouse podocytes under starved (-insulin) or insulin-stimulated (+insulin) conditions. Control and NMHC-IIA siRNA-
transfected podocyte lysates (30 µg) are included as controls. (B) Quantiﬁcation of protein levels of three replicate blots as in (A) indicates that in insulin-stimulated mouse podocytes
NMHC-IIA knockdown decreases complex formation between VAMP2 and SNAP23. (C–F) Duolink proximity ligation assay showing interaction between VAMP2 and SNAP23 in control
siRNA (C, E) and NMHC-IIA siRNA (D, F) transfected cells. Each red spot represents an interaction detected by the kit. (G) Quantiﬁcation of the spots in three replicate experiments as
in (C–F) conﬁrms the immunoprecipitation result showing that knockdown of NMHC-IIA fails to induce complex formation between VAMP2 and SNAP23. Scale bar, 30 µm. Bars show
the mean and error bars STDEV of three independent experiments, Student's t-test. * p < 0.05.
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visualized by decreased level of pp-RLC in the complex (Fig. 6A and C).
This was further validated by the Duolink proximity ligation assay
(Fig. 6D–I). Collectively, the data on septin 7 knockdown and over-
expression studies demonstrate that septin 7 enhances the complex
formation between NM-IIA and SNAP23, but reduces the activity of
NM-IIA in complex with SNAP23.
3.8. NM-IIA is activated in the glomeruli of diabetic rats
We next analyzed the expression and activity of NM-IIA in
glomeruli in vivo using obese, albuminuric Zucker rats that are insulin
resistant and slightly diabetic due to a mutation in the leptin receptor
gene [33]. Quantitative immunoblot analysis of isolated glomeruli
showed marked downregulation of NMHC-IIA in the obese (fa/fa) rats
when compared to the lean controls (fa/+) (Fig. 7A–B) and no
diﬀerence in the level of septin 7 (Fig. 7A and C), whereas the activity
of NM-IIA, visualized by increased level of pp-RLC, was signiﬁcantly
increased in the obese rats (Fig. 7A and D).
Fig. 4. Insulin regulates the activity of NM-IIA bound to SNAP23. (A) Immunoblots showing SNAP23 in immunoprecipitates obtained with septin 7 IgG but not with rabbit IgG from
starved and insulin stimulated mouse podocytes. Lysates (30 µg) are included as controls. (B) Quantiﬁcation of protein levels of three replicate blots as in (A) indicates that insulin
decreases complex formation between septin 7 and SNAP23. (C) Immunoblots showing NMHC-IIA, septin 7 and pp-RLC in immunoprecipitates obtained with SNAP23 IgG but not with
rabbit IgG from starved and insulin stimulated mouse podocytes. Lysates (30 µg) are included as controls. (D–F) Quantiﬁcation of protein levels of three replicate blots as in (C). (G–J)
Duolink proximity ligation assay showing interaction between septin 7 and SNAP23 (G, H) and between active NM-IIA (pp-RLC) and SNAP23 (I, J) in starved (G, I) and insulin
stimulated (H, J) cells. Each red spot represents an interaction detected by the kit. (K–L) Quantiﬁcation of the spots in three replicate experiments as in (G–J) showing that insulin
decreases complex formation between septin 7 and SNAP23 (K) but increases the activity of NM-IIA, visualized by an increased amount of pp-RLC, in complex with SNAP23 (L). Scale
bar, 30 µm. Bars show the mean and error bars STDEV of three independent experiments, Student's t-test. * p < 0.05.
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3.9. Macroalbuminuric sera from patients with type 1 diabetes
induce activation of NM-IIA in cultured human podocytes
We also studied the expression of septin 7, and the expression and
activity of NM-IIA in human podocytes treated with sera from male
patients with type 1 diabetes presenting either normo- or macroalbu-
minuria (Fig. 8A–D). Macroalbuminuric patients were older and had
longer duration of diabetes, as expected based on their diabetes status
(Supplemental Table S1). The expression of NMHC-IIA and septin 7
did not diﬀer between the groups (Fig. 8A–C). Interestingly, the
activity of NM-IIA, visualized by increased level of pp-RLC, was
increased by 75% in podocytes treated with sera from macroalbumi-
nuric patients compared to podocytes treated with sera from normoal-
buminuric patients (Fig. 8A and D). Furthermore, Duolink proximity
Fig. 5. Knockdown of septin 7 reduces the amount but increases the activity of NM-IIA in complex with SNAP23. (A) Immunoblots showing NMHC-IIA, septin 7 and pp-RLC in
immunoprecipitates obtained with SNAP23 IgG but not with rabbit IgG from control or septin 7 siRNA transfected mouse podocytes. Control and septin 7 siRNA-transfected podocyte
lysates (30 µg) are included as controls. (B–C) Quantiﬁcation of protein levels of three replicate blots as in (A) indicates that septin 7 knockdown decreases complex formation between
NMHC-IIA and SNAP23. However, septin 7 knockdown increases the activity of NM-IIA in complex with SNAP23 visualized by an increased level of pp-RLC in the precipitate. (D–G)
Duolink proximity ligation assay shows interactions between NMHC-IIA and SNAP23 (D, E), and pp-RLC and SNAP23 (F, G) in control siRNA (D, F) and NMHC-IIA siRNA (E, G)
transfected podocytes. Each red spot represents an interaction detected by the kit. (H–I) Quantiﬁcation of the spots in three replicate experiments as in (D–G) conﬁrms the
immunoprecipitation result showing that knockdown of septin 7 decreases complex formation of NMHC-IIA with SNAP23, and increases the activity of NM-IIA in complex with
SNAP23. (J) Immunoblots showing unchanged expression level of NMHC-IIA and pp-RLC in septin 7 depleted cells compared to the control siRNA-treated cells. (K-M) Quantiﬁcation of
protein levels of three replicate blots as in (J). Scale bar, 30 µm. Bars show the mean and error bars STDEV of three independent experiments, Student's t-test. * p < 0.05.
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Fig. 6. Septin 7 overexpression increases the amount but reduces the activity of NM-IIA in complex with SNAP23. (A) Immunoblots showing NMHC-IIA, septin 7 and pp-RLC in
immunoprecipitates obtained with SNAP23 IgG but not with rabbit IgG from septin 7 or vector only transfected mouse podocytes. Lysates of podocytes overexpressing septin 7 or vector
only (30 µg) are included as controls. (B–C) Quantitation of protein levels of three replicate blots as in (A) reveals that septin 7 overexpression increases complex formation of NMHC-
IIA with SNAP23. However, septin overexpression decreases the activity of NM-IIA in complex with SNAP23. (D–G) Duolink proximity ligation assay shows interactions between
NMHC-IIA and SNAP23 (D, E), and pp-RLC and SNAP23 (F, G) in vector only (D, F) and septin 7 (E, G) overexpressing podocytes. Each red spot represents an interaction detected by
the kit. (H-I) Quantiﬁcation of the spots in three replicate experiments as in (D–G) conﬁrms the immunoprecipitation result showing that overexpression of septin 7 increases complex
formation of NM-IIA with SNAP23, but decreases the activity of NM-IIA found in complex with SNAP23. Scale bar, 30 µm. Bars show the mean and error bars STDEV of three
independent experiments, Student's t-test. * p < 0.05, ** p < 0.01.
Fig. 7. NM-IIA is activated in glomeruli of diabetic rats. (A) Immunoblotting for NMHC-IIA, septin 7 and pp-RLC shows that NMHC-IIA is downregulated whereas the activity of NM-
IIA is increased, visualized by an elevated level of pp-RLC, in glomeruli of obese Zucker rats compared to lean controls. The expression level of septin 7 does not change. Actin is included
as a loading control (n=6 in each group). (B–D) Quantiﬁcation of the levels of NMHC-IIA, septin 7 and pp-RLC in (A) normalized to actin. Bars show the mean and error bars STDEV of
three independent experiments, Student's t-test. * p < 0.05.
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ligation assay on human podocytes treated with sera form normo- and
macroalbuminuric patients revealed, despite large variation, decreased
interaction between septin 7 and SNAP23 after treatment with sera
from patients presenting macroalbuminuria (Fig. 8E–G).
4. Discussion
NMHC-IIA is expressed in glomerular podocytes and has been
suggested to function as a major component of the actin-myosin
contractile apparatus, which helps podocytes to respond to changes
in the glomerular pressure in physiological conditions and contributes
to foot process retraction in pathological conditions [26]. Here we
Fig. 8. Macroalbuminuric sera from human patients with type 1 diabetes activate NM-IIA in cultured human podocytes. (A) The activity of NM-IIA, visualized by increased level of pp-
RLC, is increased by 75% in human podocytes treated with macroalbuminuric sera from patients with type 1 diabetes compared to treatment with normoalbuminuric sera. The
expression levels of NMHC-II and septin 7 do not change. Tubulin is included as a loading control. (B–D) Quantiﬁcation of the expression levels of NMHC-IIA, septin 7 and pp-RLC in
(A) normalized to tubulin. (E–F) Duolink proximity ligation assay showing interaction between septin 7 and SNAP23 in podocytes treated with sera from patients with type 1 diabetes
presenting either normo- or macroalbuminuria. Each red spot represents an interaction detected by the kit. (G) Quantiﬁcation of the spots as in (E–F). Scale bar, 30 µm. Bars show the
mean and error bars STDEV of two independent experiments, Student's t-test. * p < 0.05.
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present another function for NMHC-IIA as a regulator of GSV
traﬃcking and glucose uptake in podocytes. We show that knockdown
of NMHC-IIA reduces insulin-induced glucose uptake in podocytes.
Furthermore, we found that the small GTPase septin 7 reduces the
activity of NM-IIA in the SNAP23 complex proposing a new mechan-
ism by which septin 7 and NM-IIA regulate glucose uptake into
podocytes.
We previously found that septin 7 binds to the v-SNARE VAMP2
and reduces glucose uptake in HIRc cells (rat ﬁbroblasts stably
expressing human insulin receptor) and podocytes by apparently
forming a barrier between the GSVs and the plasma membrane [12].
Here we show that septin 7 also binds to the t-SNARE SNAP23
suggesting that septin 7 could also be involved in the regulation of
the docking process. We further observed that septin 7 forms a complex
with NMHC-IIA, and that NMHC-IIA is necessary for insulin-stimu-
lated glucose uptake into podocytes. The importance of NMHC-IIA in
glucose uptake is supported by studies in adipocytes, in which
pharmacological inhibition of the activity of NM-II or knockdown of
NM-IIA reduced insulin-stimulated glucose uptake [13–15]. Our
observations provide an insight how insulin-stimulated glucose uptake
into podocytes is mechanistically regulated by septin 7 and NMHC-IIA.
We found that insulin reduces the amount of septin 7 in the SNAP23
complex, and increases the activity of NM-IIA (an increase in pp-RLC)
in the complex, thereby enhancing docking and fusion of GSVs with the
plasma membrane and uptake of glucose into podocytes. Supporting
our data, blocking the phosphorylation of RLC inhibits GSV transloca-
tion and glucose uptake in adipocytes [28].
We found that in podocytes, knockdown of NMHC-IIA inhibits the
insulin-stimulated interaction between SNAP23 and VAMP2, the t-
SNARE and v-SNARE involved in GSV docking and fusion. Also in
adipocytes knockdown of NMHC-IIA inhibits t-SNARE/v-SNARE
(syntaxin 4/VAMP2) complex formation [15]. SNAP23 appears central
for the insulin-stimulated regulatory actions of septin 7 and NM-IIA in
glucose uptake in podocytes, as insulin stimulation reduces the
interaction of septin 7 with SNAP23 and enhances the activity of
NM-IIA in complex with SNAP23 (Fig. 9). Septin 7 knockdown,
similarly as insulin stimulation, increases the activity of NM-IIA in
the SNAP23 complex; yet we acknowledge that the signaling pathways
activated by insulin stimulation and septin 7 knockdown may vary.
Septin 7 overexpression has opposite eﬀects further conﬁrming the
ﬁnding. These data together suggest that septin 7 plays a central role in
GSV docking and fusion by regulating the activity of NM-IIA in the
SNAP23 complex.
Previous data have revealed diﬀerential eﬀects of various septins on
the activity of myosins. Septin 9, which we previously found to be in
complex with septin 7 in podocytes and downregulated upon septin 7
knockdown [12], has been shown to inhibit the actin-dependent
ATPase activity of myosin V [34]. Septin 2, on the other hand, has
been shown to scaﬀold NM-II and its kinases to activate NM-II by
phosphorylation of the RLC [35]. These data, together with our results
here, illustrate the complex relationship between the members of the
septin and myosin families, which may cooperate in diﬀerent manner
in diﬀerent cell types. Thus, further studies are required to determine
the exact mechanisms by which septin 7 reduces the activity of NM-IIA
in the SNAP23 complex in podocytes. One possible mechanism by
which septin 7 may regulate the activity of NM-IIA in the SNAP23
complex is via recruitment of a phosphatase, the identity of which
remains to be characterized. We can not rule out the possibility that
NM-IIA regulates the ﬁnal steps of GSV traﬃcking also via modulating
actin dynamics, as the activity of NM-IIA is necessary for F-actin
localization at the plasma membrane in adipocytes [36], and knock-
down of NMHC-IIA leads to loss of actin stress ﬁber organization in
podocytes [37]. Defective actin remodeling impairs the fusion of GSVs
with the plasma membrane in adipocytes [38] and muscle cells [39],
and glucose uptake depends on an intact actin cytoskeleton also in
podocytes [8]. NM-IIA also regulates the intrinsic activity of GLUT4 at
the plasma membrane after insulin stimulation [14], and also other
proteins may, either positively or negatively, regulate GLUT4 activity
[40], indicating the complexity of GLUT4 regulation.
Interestingly, we found that the activity of NM-IIA is increased in
glomeruli of obese and albuminuric Zucker rats. Furthermore, we
observed that exposure of cultured human podocytes to macroalbumi-
nuric sera from patients with type 1 diabetes decreases the association
between septin 7 and SNAP23 and increases the activation of NM-IIA
compared to podocytes treated with normoalbuminuric sera. This
indicates that some factors in the macroalbuminuric sera activate
NM-IIA and may thereby enhance GSV docking and fusion and glucose
uptake into podocytes. Further support for a role for NM-IIA and
associated kinases in DN is provided in a study showing that the
expression of myosin light chain kinase increases in the kidneys in
streptozotocin-induced diabetes [41]. In addition, polymorphisms in
MYH9, which encodes NMHC-IIA, are associated with DN in European
Americans [42]. Whether increased glucose uptake by an increase in
active NM-IIA in diabetes is protective or predisposes to DN awaits
further studies. Excess glucose may activate several pathways that lead
to podocyte injury [43]. The protective eﬀect, on the other hand, could
be expected based on data showing that insulin signaling, which may be
coupled to increased glucose uptake, is essential for normal kidney
function [9]. Furthermore, several clinical and experimental studies
show that many, although not all, insulin sensitizers reduce albumi-
nuria [44].
Both septin 7 and NMHC-IIA are in complex with nephrin (this
study and [12]), an essential component of the interpodocyte cell
adhesion structure called slit diaphragm [45]. Nephrin associates with
the actin cytoskeleton [46] and serves as a modifying protein in the
SNARE complex by associating with VAMP2 [9]. It is possible that in
podocytes nephrin determines the speciﬁc membrane domain for NM-
IIA and associated SNARE proteins to facilitate the docking and fusion
of GSVs in the slit diaphragm region. As GLUT4 was previously found
widely distributed in podocytes [8], other proteins than nephrin are
apparently involved in the docking and fusion of GSVs in the basal and
apical domains of the podocyte foot processes. The association of
nephrin with NMHC-IIA suggests that nephrin could also play a role in
syndromes associated with MYH9, so called MYH9-related disorders
[47–49], as some patients with MYH9 mutations develop progressive
proteinuric renal disease. However, the molecular mechanisms under-
lying the renal phenotype have thus far remained unclear. In mice,
mutations in Myh9 mimicking the mutations identiﬁed in human
MYH9-associated diseases or podocyte-speciﬁc deletion of Myh9 may
lead to kidney dysfunction or predispose the mice to glomerulopathy
depending on the genetic background and the type of the experimental
injury [50–52]. Further studies analyzing the glucose uptake activity of
the podocytes in these models will help to determine the role of
NMHC-IIA in the insulin responsiveness of podocytes in vivo, and
clarify whether this could be associated with the development of
Fig. 9. A cartoon showing the mechanism by which insulin stimulation regulates GSV
docking and fusion in podocytes via septin 7 and NM-IIA. Septin 7, together with other
septins in the complex, forms a barrier underneath the plasma membrane. This hinders
the movement of GSVs and interaction of VAMP2 with SNAP23. Insulin stimulation
triggers reduction of septins in complex with SNAP23 and increases activation of NM-IIA
as revealed by an elevated level of phosphorylation of myosin RLC (pp-RLC). This
enhances complex formation between VAMP2 and SNAP23 and thereby docking and
fusion of the GSVs with the plasma membrane, leading to increased uptake of glucose
into podocytes.
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MYH9-associated glomerulopathy.
In addition to MYH9-related disorders, NMHC-IIA has also been
associated with focal segmental glomerulosclerosis (FSGS) and end-
stage renal disease [53]. Sekine et al. [54] suggested that mutations in
NMHC-IIA could impair the structure and function of the slit
diaphragm, which would result in proteinuria and the development
of FSGS [54]. Our observation that NMHC-IIA and nephrin are found
in the same multiprotein complex supports this. Further studies are
required to deﬁne how the mutations inMYH9might aﬀect nephrin, its
protein complexes, association with actin, and other functions, includ-
ing the potential role of NM-IIA in regulating the insulin sensitivity of
podocytes. This may provide novel clues to understanding the mechan-
isms that underlie disorders caused by mutations in MYH9.
In conclusion, we show here that NMHC-IIA is essential for insulin-
stimulated glucose uptake into podocytes, and that SNAP23 and septin
7 are central regulators of the process. Interaction of NM-IIA with
nephrin further suggests that NM-IIA may be involved in the regula-
tion of the composition or function of the slit diaphragm.
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